The world has been afflicted with elevational sickness (ES), a debilitating condition in which people can’t walk upright because of low blood pressure.
Now, an international team of researchers has developed a new method to detect the condition in humans and to treat it, according to a press release from the University of Michigan.
Elevated COVID-19 is an airborne virus that can cause the body to release a toxin that leads to respiratory problems.
Elevation sickness is usually a mild or moderate illness with no symptoms.
Researchers are currently developing a new test to detect elevation sickness in humans.
The new test, developed by the Michigan team, will be published in the Journal of Clinical Microbiology on December 7.
The researchers used blood samples to monitor how well the body responded to the test.
The results showed that people with elevated COVID symptoms had a 50 percent increased risk of developing elevation sickness compared to people with lower levels of COVID.
In addition, there were also differences in the response to the tests, according the press release.
“Elevation sickness may be an important contributor to the spread of the coronavirus, particularly among children, older adults and those who are more vulnerable to COVID, as it can result in increased risk for COVID transmission,” Dr. John R. Bresnik, professor of infectious diseases and microbiology and director of the University’s Center for Infectious Diseases, said in the press report.
The team also used the new test in a study to help people with COVID diagnosed with elevated sickness.
The study found that if people with the elevated COVIS-19 levels were tested at a hospital, they were 50 percent more likely to get elevated COVE-19 symptoms, and that if they were tested after a hospitalization, they had an increased risk.
Researchers also found that the tests are highly sensitive and can detect elevated COVI-19 even after an infection has occurred.
It is possible that some of the elevated levels could have been caused by the COVID virus, but Dr. Bregnik said they do not know that yet.
“We’re excited about this new approach,” he said in a press statement.
“There are many other diseases that cause elevations of COVIS or COVID infection, but COVID is probably the first one to be targeted in humans.”
Dr. Daniel E. Kline, a professor of medicine and director for infectious diseases at the University, said the study was a huge step forward in detecting COVID disease in humans, but that further research is needed.
“This is a first step towards better diagnosing COVID and for treating it, as well as diagnosing the underlying cause of elevation sickness,” Dr Kline said.
“More research is required to determine if this new test will also be useful in detecting elevated COV-19 infection in humans in the future.”